Pregnancy Discrimination Act

The Pregnancy Discrimination Act (PDA) is a federal law that prohibits employers from discriminating against employees or job applicants based on pregnancy, childbirth, or related medical conditions. The law applies to employers with 15 or more employees and covers a wide range of employment practices, including hiring, firing, promotions, and compensation.

Key features of the Pregnancy Discrimination Act include:

  • Prohibition of Discrimination: Employers are prohibited from discriminating against employees or job applicants based on pregnancy, childbirth, or related medical conditions.

  • Accommodations: Employers are required to provide reasonable accommodations to pregnant employees, such as modified work schedules, light duty assignments, or temporary transfers, as long as the accommodations do not create an undue hardship for the employer.

  • Health Insurance: Health insurance provided by an employer must cover expenses related to pregnancy and childbirth in the same way as other medical conditions.

  • Parental Leave: The PDA does not provide for specific parental leave, but it requires that employers treat pregnant employees the same as other employees who are similarly situated in their ability to work. Therefore, if an employer provides leave or other accommodations to employees who are temporarily disabled, it must also provide leave or other accommodations to pregnant employees.

The PDA is an amendment to Title VII of the Civil Rights Act of 1964 and is enforced by the Equal Employment Opportunity Commission (EEOC). Violations of the PDA can result in legal action, including back pay, compensatory and punitive damages, and injunctive relief.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.